A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Launched by NOVO NORDISK A/S · Jun 20, 2017
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- • Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial - Male patients aged 18 years or older at the time of signing informed consent, diagnosed with severe haemophilia A (FVIII activity below 1%), based on medical records or results at screening Exclusion Criteria: - Known or suspected hypersensitivity to trial product(s) or related products - Known inherited or acquired bleeding disorder other than haemophilia A - Presence of inhibitors (neutralising antibodies) to Factor VIII (equal to or above 0.6 Bethesda Units) at screening measured by the Nijmegen method
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Brest, , France
Oklahoma City, Oklahoma, United States
Valencia, , Spain
Indianapolis, Indiana, United States
Madrid, , Spain
Bornova Izmir, , Turkey
Bangkok, , Thailand
Nantes Cedex 1, , France
Milano, , Italy
Caen, , France
Homburg, , Germany
Malmö, , Sweden
Málaga, , Spain
Milano, , Italy
Ankara, , Turkey
London, , United Kingdom
Nashville, Tennessee, United States
Bonn, , Germany
Cambridge, , United Kingdom
Tokyo, , Japan
Aichi, , Japan
Nara, , Japan
Salt Lake City, Utah, United States
Lviv, , Ukraine
Rome, , Italy
London, , United Kingdom
Solna, , Sweden
Edirne, , Turkey
İstanbul, , Turkey
Belfast, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials